Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-
axonal injury. The advent of highly sensitive analytical platforms that enable reliable …

Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal
damage as well as its quantification is a critical step for patients. Blood-based serum …

Importance There is a lack of validated biomarkers for disability progression independent of
relapse activity (PIRA) in multiple sclerosis (MS). Objective To determine how serum glial …

One of the biggest challenges in managing multiple sclerosis is the heterogeneity of clinical
manifestations and progression trajectories. It still remains to be elucidated whether this …

Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically
useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There …

Neuronal injury is a universal event that occurs in disease processes that affect both the
central and peripheral nervous systems. A blood biomarker linked to neuronal injury would …

Background Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that
is used not only to monitor disease activity and response to drugs and to prognosticate …

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …

Multiple sclerosis (MS) is an autoimmune, inflammatory neurodegenerative disease of the
central nervous system characterized by demyelination and axonal damage. Diagnosis and …

Parkinson's Disease (PD) is a highly prevalent neurodegenerative disease among older
adults. PD neuropathology is marked by the progressive loss of the dopaminergic neurons …